CompletedNot Applicable

Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)

Turkey (Türkiye)88 participantsStarted 2018-03-01

Plain-language summary

Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. There are many studies about AMH changes in ovarian surgery, but little is known for other surgeries. We seek to investigate the hormone variations before and after uterine artey ligation for postpartum hemorrage (PPH)

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age 18- 40 years * no systemic or endocrine diseases * patients who had uterine artery ligation due to PPH Exclusion Criteria: * Pregnancy with IVF or oosit donation * Patients with endocrinopathy, diseases which require radiotherapy and chemotherapy etc. * Patients with BMI \>40

What they're measuring

1- Anti-Mullerian Hormone levels variation

Timeframe: 3 months

Trial details

NCT IDNCT03907605

SponsorKanuni Sultan Suleyman Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-03-01

View on ClinicalTrials.gov More Anti-Mullerian Hormone Deficiency trials